CD274 and non-small cell lung carcinoma: Only a fraction of patients with advanced non-small cell lung cancer (NSCLC), the most common type of lung cancer, experience clinical benefit from targeted agents or single-agent ICIs, as this is dependent on the mutational profile and programmed death-ligand 1 (PD-L1) expression status, respectively [4].